Suven Life Sciences Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 24.51 million compared to INR 30.02 million a year ago. Revenue was INR 85.16 million compared to INR 52.07 million a year ago. Net loss was INR 417.65 million compared to INR 511.15 million a year ago. Basic loss per share from continuing operations was INR 1.92 compared to INR 2.9 a year ago. Diluted loss per share from continuing operations was INR 1.92 compared to INR 2.9 a year ago.
For the nine months, sales was INR 93.08 million compared to INR 109.28 million a year ago. Revenue was INR 261.55 million compared to INR 137.75 million a year ago. Net loss was INR 785.36 million compared to INR 906.23 million a year ago. Basic loss per share from continuing operations was INR 3.6 compared to INR 5.46 a year ago. Diluted loss per share from continuing operations was INR 3.6 compared to INR 5.46 a year ago.